Peter T Bartels AO, FAISM, FRS
Chairman and Non-executive Director
Mr. Bartels has considerable experience in the Pharmaceutical industry; while working for Abbott Laboratories he was responsible for the introduction of a wide range of industrial, agricultural, veterinary and human pharmaceuticals into the Australian market. He was a director of Drug Houses of Australia and was managing director of DHA Pharmaceuticals. He has been a major player in corporate Australia, having held the positions of CEO and Managing Director of both Coles Myer Ltd and Fosters Brewing Company Ltd. He is a past Chairman of the Australian Sports Commission, the Australian Institute of Sport, the Commonwealth Heads of Government Committee for Sport and the Royal Women's and Royal Children's Hospitals. Peter is presently Chair of the Dean's external Advisory Council for the Faculty of Medicine, Dentistry and Health Sciences at The University of Melbourne.
Jackie Fairley, BSc, BVSc (Hons), MBA
Chief Executive Officer
Dr Jackie Fairley has more than 20 years of operational experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding (now Hospira). She was appointed Chief Executive Officer of Starpharma Holdings Ltd in July 2006. Jackie holds first class honours degrees in Science and Veterinary Science from Melbourne University and was a practicing veterinary surgeon prior to joining CSL in 1989. Whilst at CSL she obtained an MBA from the Melbourne Business School where, as Dux of her final year, she was the recipient of the prestigious Clemenger Medal and a number of other academic prizes. Jackie currently sits on the board of the Melbourne Business School, and is a past member of the Federal Government’s Pharmaceutical Industry Working Group and the Federal Ministerial Biotechnology Advisory Council. She is also an advisor to the Carnegie Innovation Fund.
Ross Dobinson, BBus (Acc)
Non-executive Director
Mr Dobinson is a merchant banker with a background in investment banking and stockbroking. He has acted as Corporate Director for two leading stockbrokers, and was Executive Director of the NAB’s corporate advisory subsidiary. He later headed the corporate advisory division of Dresdner Australia Ltd. Mr Dobinson is currently Managing Director of TSL Group Ltd, a corporate advisory company specialising in establishing and advising life science companies. He is Chairman of listed company Acrux Ltd, and is also a Director of a number of unlisted companies.
Richard A Hazleton, BSChE, MSChE, HonDrEngr, HonDrCommSci
Non-executive Director
Mr Hazleton is retired chairman and CEO of Dow Corning Corporation, a Michigan-based multinational producer of specialty chemicals and materials. Mr Hazleton began his Dow Corning career in 1965. He held numerous positions in engineering, manufacturing and finance, both in the US and Europe, before becoming CEO of the company in 1993, and Chairman of the Board of Directors and CEO in 1994. He retired in 2001.Mr Hazleton has served on the Boards of the American Chemistry Council and the Chemical Bank and Trust Company. He served as Chairman of the Board of DNT Inc. from 2004 until the company was acquired by Starpharma in October 2006. Hazleton holds bachelors and masters degrees in chemical engineering from Purdue University, and earned a master of business administration degree from Central Michigan University.
Peter J Jenkins, MB, BS (Melb), FRACP
Non-executive Director
Dr Jenkins is a consultant physician and gastroenterologist who holds clinical and research positions with the Alfred Hospital, and has held clinical research positions with the Baker Medical Research Centre. He is a former judge of the Australian Technology Awards and is Executive Director of AusBio Ltd, an unlisted public biotechnology company.
Zita Peach, BSc
Non-executive Director
Ms Peach has more than 20 years of commercial experience in the pharmaceutical industry, particularly in marketing and business development, working for major industry players such as CSL Limited and Merck Sharp & Dohme (MSD), the Australian subsidiary of Merck Inc. She is currently the Managing Director and Executive Vice President, South Asia Pacific for Fresenius Kabi Australia, a leader in infusion therapy and clinical nutrition. Until recently Ms Peach was Vice President/Director, Business Development R&D for CSL, a position she held for ten years. Ms Peach is also a Board Member of BioMelbourne Network, and a Non-Executive Director of the ASX-listed Vision Eye Institute Limited.
Peter R. Turvey, BA/LLB, MAICD
Non-executive Director
Peter Turvey is the former Executive Vice President Licensing and Company Secretary of global specialty biopharmaceutical company CSL Limited having retired in 2011. He is currently a Principal of Foursight Associates Pty Ltd and a director of the industry organisation AusBiotech Limited. After completing an Arts/Law degree at the Australian National University, he joined Biotechnology Australia, then Australia's largest biotechnology company, as Manager of Intellectual Property and Company Secretary. He joined CSL in 1992 as its first in-house Corporate Counsel and was appointed Company Secretary in 1998. He played a key role in the transformation of CSL from a government owned enterprise, through ASX listing in 1994, to a global plasma and biopharmaceutical company. He also had responsibility for the protection and licensing of CSL's intellectual property and for risk management within CSL, which included management of the internal audit function, reporting to the Audit & Risk Management Committee of the Board as well as being the Chairman of the Corporate Risk Management Committee. Among the many licensing deals he was involved with, the most significant included the Gardasil license to Merck & Co., the licensing of the Iscomatrix® adjuvant platform technology to the world’s leading vaccine manufacturers, and establishment of the P.gingivalis vaccine technology collaboration between the CRC for Oral Health and Sanofi-Pasteur.